CSCO guidelines for colorectal cancer version 2024:Updates and discussions  

作　　者：Liubo Chen Hanguang Hu Ying Yuan Shanshan Weng 

机构地区：[1]Department of Medical Oncology(Key Laboratory of Cancer Prevention and Intervention,China National Ministry of Education,Key Laboratory of Molecular Biology in Medical Sciences,Zhejiang Province,China),the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China [2]Zhejiang Provincial Clinical Research Center for CANCER,Hangzhou 310009,China [3]Cancer Center,Zhejiang University,Hangzhou 310058,China

出　　处：《Chinese Journal of Cancer Research》2024年第3期233-239,共7页中国癌症研究（英文版）

基　　金：supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125);National Natural Science Foundation of China(No.82373415 and No.82302489);Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003).

摘　　要：According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevalent cancer,following only after lung cancer(2).The first version of the Chinese Society of Clinical Oncology(CSCO)guideline was launched in 2017 and has been updated annually based on the latest findings of clinical research,drug accessibility and expert consensus(3-8).Here,we present the main updates of the 2024 version compared to the 2023 version.

关 键 词：CSCO COLORECTAL CANCER 

分 类 号：R735.34[医药卫生—肿瘤]